1. Moleculin Biotech announces warrant exercises for 727,969 shares at $6.63 each. 2. The warrant exercise is expected to raise approximately $6.5 million. 3. New warrants will be issued for up to 2,610,823 shares, subject to shareholder approval. 4. The funds will be used for working capital and general corporate purposes. 5. Moleculin is advancing its clinical programs targeting severe cancers and viruses.
FAQ
Why Bullish?
The cash influx from warrant exercises will strengthen MBRX's financial position, historically leading to positive price movements.
How important is it?
The financial and operational enhancements directly relate to MBRX's share value potential.
Why Short Term?
The announcement is immediate, with potential stock price movement expected around the closing date.
Moleculin Biotech, Inc. (Nasdaq: MBRX) Announces Immediate Exercise of Warrants for $6.8 Million Gross Proceeds
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) – Moleculin Biotech, Inc. (Nasdaq: MBRX), a pioneering late-stage pharmaceutical company focused on developing treatments for hard-to-treat tumors and viral infections, has made an important announcement regarding its financial strategy. The company has entered into agreements with holders of its existing warrants for the immediate exercise of those warrants, which is anticipated to yield gross proceeds of approximately $6.5 million.
Details of the Warrant Exercise Agreements
Moleculin will allow the immediate exercise of outstanding warrants, enabling the purchase of up to a total of 727,969 shares of its common stock issued in February 2025 at an exercise price of $6.63 per share. Additionally, it will include 316,360 shares from warrants issued in August 2025, priced at $6.3219 each. The shares are registered under effective registration statements on Form S-1 (File No. 333-286276) and Form S-3 (File No. 333-290418).
As a component of this exercise, Moleculin plans to issue new unregistered warrants for the purchase of up to 2,610,823 shares, also priced at $6.63 per share. These new warrants will be exercisable upon shareholder approval and will remain valid for five years following that approval.
Transaction and Financial Advisors
The completion of this transaction is expected around December 11, 2025, pending the satisfaction of customary closing conditions. The financial advisory services for this transaction are being provided by Roth Capital Partners and Maxim Group LLC.
The net proceeds from the exercise of these warrants will be allocated for operational capital and general corporate needs. Furthermore, the new warrants are offered in a private placement, adhering to exemptions from the registration requirements laid out by the Securities Act of 1933.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is actively involved in Phase 3 clinical trials, with a robust pipeline of therapeutic candidates targeting difficult tumors and viral diseases. The company’s primary candidate, Annamycin, is a next-generation anthracycline designed to bypass multidrug resistance and avoid the cardiotoxic side effects associated with current therapies. It is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The MIRACLE Trial (MB-108), evaluating Annamycin in combination with cytarabine, represents a pivotal step towards an expected potential approval for AML treatment. With insights from the FDA and results from a successful Phase 1B/2 study (MB-106), Moleculin believes it has substantially de-risked this development pathway.
Forward-Looking Statements
This announcement contains forward-looking statements as defined under relevant securities regulations, which involve inherent risks and uncertainties. Such statements include, but are not limited to, anticipated timelines and resource allocation expectations related to the transaction. Moleculin Biotech, Inc. cautions that actual results may materially differ, and stakeholders should refer to the latest public filings for detailed risk factors.
Investor Relations
For more information, investors can contact:
- JTC Team, LLC
- Jenene Thomas
- Phone: (908) 824-0775
- Email: MBRX@jtcir.com